- Home
- TRAW vs KPRX Comparison
TRAW vs KPRX Comparison
Compare TRAW & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRAW
- KPRX
- Stock Information
- Founded
- TRAW 1998
- KPRX 1998
- Country
- TRAW United States
- KPRX United States
- Employees
- TRAW N/A
- KPRX N/A
- Industry
- TRAW
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TRAW
- KPRX Health Care
- Exchange
- TRAW NYSE
- KPRX Nasdaq
- Market Cap
- TRAW 8.6M
- KPRX 9.1M
- IPO Year
- TRAW 2013
- KPRX N/A
- Fundamental
- Price
- TRAW $1.48
- KPRX $2.82
- Analyst Decision
- TRAW
- KPRX Strong Buy
- Analyst Count
- TRAW 0
- KPRX 1
- Target Price
- TRAW N/A
- KPRX $10.00
- AVG Volume (30 Days)
- TRAW 3.4M
- KPRX 1.4M
- Earning Date
- TRAW 08-14-2025
- KPRX 08-08-2025
- Dividend Yield
- TRAW N/A
- KPRX N/A
- EPS Growth
- TRAW N/A
- KPRX N/A
- EPS
- TRAW N/A
- KPRX N/A
- Revenue
- TRAW $227,000.00
- KPRX $20,000.00
- Revenue This Year
- TRAW $3.81
- KPRX N/A
- Revenue Next Year
- TRAW $30.43
- KPRX N/A
- P/E Ratio
- TRAW N/A
- KPRX N/A
- Revenue Growth
- TRAW 0.44
- KPRX N/A
- 52 Week Low
- TRAW $0.97
- KPRX $2.51
- 52 Week High
- TRAW $19.44
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- TRAW 43.63
- KPRX 40.86
- Support Level
- TRAW $1.37
- KPRX $2.87
- Resistance Level
- TRAW $1.49
- KPRX $3.22
- Average True Range (ATR)
- TRAW 0.11
- KPRX 0.18
- MACD
- TRAW -0.03
- KPRX -0.03
- Stochastic Oscillator
- TRAW 12.07
- KPRX 21.20
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.